GleamWall
中文EN

SGMOQ SANGAMO THERAPEUTICS, INC

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1001233 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-31.6%
TTM net income YoY-25.5%
TTM EPS YoY10.2%
Revenue 3-yr CAGR-29.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-306.5%
Net margin-310.8%
FCF margin-246.0%
EBITDA margin-296.5%

Returns

ROE-2,891.8%
ROA-152.4%
ROIC (approx.)—
Asset turnover0.49x

Leverage & solvency

Liabilities / assets123.9%
Debt / equity—
Current ratio0.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-31.9%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$39.55M$57.80M
R&D expense$112.67M$111.52M
SG&A expense$34.89M$44.73M
Operating income-$121.24M-$103.97M
Pretax income-$123.50M-$98.11M
Income tax-$568,000-$167,000
Net income-$122.93M-$97.94M
EBITDA-$117.28M-$98.86M
EPS (basic)-0.44-0.49
EPS (diluted)-0.44-0.49
Weighted avg. shares (diluted)280.19M201.70M
Balance sheet
Cash & equivalents$20.95M$41.92M
Receivables$371,000$526,000
Current assets$35.83M$51.69M
PP&E, net$11.04M$17.89M
Goodwill—$0
Intangibles—$0
Total assets$59.74M$101.64M
Current liabilities$42.47M$45.80M
Total liabilities$74.01M$78.86M
Shareholders' equity-$14.27M$22.77M
Shares outstanding350.69M212.84M
Cash flow statement
Operating cash flow-$97.21M-$67.14M
Capital expenditure$102,000$267,000
Free cash flow-$97.31M-$67.41M
Investing cash flow-$102,000$37.52M
Financing cash flow$70.75M$28.38M
Depreciation & amortization$3.96M$5.11M
Stock-based compensation$9.08M$12.38M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.